


Curriculum Vitae

 Photo	Name (First Name, Middle Name Last Name)	Sang Hyoung Park
	Position	Associate Professor
	Affiliation	Department of Gastroenterology, University of Ulsan College of Medicine, Asan Medical Center
	Country	Korea
	Major Field	Gastroenterology

Education Background
Dr. Park received his medical degree from University of Ulsan College of Medicine in Korea in 2003. He completed his internship and residency in internal medicine at the Asan Medical Center in Seoul, Korea. Dr. Park served as a medical officer at Korean Army from 2008-2010. He completed a fellowship in gastroenterology from 2011-2012 at the Asan Medical Center.
Professional Experience
Since 2014, Dr. Park had been working as an assistant professor of gastroenterology at the Asan Medical Center. Between 2016 and 2018, he underwent an oversea training for 2 years at the Mayo clinic, Rochester, Minnesota. He worked as a visiting research fellow under the supervision of Dr. Edward Loftus in IBD interest group of Mayo clinic for 1 year, then completed an advanced IBD clinical fellowship at the Mayo Graduate School of Medicine. Since 2019, Dr. Park has been working as an associate professor of gastroenterology at the Asan Medical Center.
Professional Organizations
Associate Editor of Crohn's & Colitis 360 (an official publication of the Crohn's & Colitis Foundation) since 2019
Scientific Publication
Papers, Books, etc. presented or published by your name (within 5 years)
1. Oh K, Kwon EJ, Kim JH, et al. Medication adherence in Korean patients with inflammatory bowel disease and its associated factors. <i>Ewha Med J</i> 2022. (co-corresponding author)
2. Choi MG, Ye BD, Yang SK, et al. The risk of tuberculosis in patients with inflammatory bowel disease treated with vedolizumab or ustekinumab in South Korea. <i>J Korean Med Sci</i> 2022. (co-corresponding author)
3. Kim K, Hong HS, Oh K, et al. Oral beclomethasone dipropionate as an add-on therapy and response prediction in Korean patients with ulcerative colitis. <i>Korean J Intern Med</i> 2022. (corresponding author)
4. Lee JW, Song EM, Jung S, et al. Clinical course of COVID-19 in patients with inflammatory bowel disease in Korea: A KASID multicenter study. <i>J Korean Med Sci</i> 2021 Dec 13;36(48):e336. (corresponding author)
5. Lee JY, Oh K, Hong HS, et al. Risk and characteristics of tuberculosis after anti-tumor necrosis factor therapy for inflammatory bowel disease: A hospital-based cohort study from Korea. <i>BMC Gastroenterol</i> 2021 Oct 20;21(1):390. (co-corresponding author)
6. Park SH. Update on the epidemiology of inflammatory bowel disease in Asia: Where are we now? <i>Intest Res</i> 2021 [Epub ahead of print]
7. Ahn SM, Choi J, Ye BD, et al. Risk of Hepatitis B Virus Reactivation in Patients with Immune-Mediated Inflammatory Diseases Receiving Biologics: Focus on the Timing of Biologics after Anti-HBV Treatment. <i>Gut Liver</i> 2021 [Epub ahead of print] (co-corresponding author)
8. Hong HS, Kim K, Oh K, et al. Short-term tolerability and effectiveness of methotrexate monotherapy in adult patients with Crohn's disease: A retrospective study. <i>Therap Adv Gastroenterol</i> 2021 Sep 13;14:17562848211043017. (corresponding author)
9. Kim SG, Lee HS, Kim BJ, et al. The clinical features of inflammatory bowel disease in patients with obesity. <i>Can J Gastroenterol Hepatol.</i> 2021 Aug 2;2021:9981482. (corresponding author)

10. Park SH, Im JP, Park H, et al. Clinical features and long-term outcomes of pediatric-onset inflammatory bowel disease in a population-based cohort in the Songpa-Kangdong district of Seoul, Korea. *J Crohns Colitis*. 2021 [Epub ahead of print]
11. Ahn HJ, Kim YJ, Lee HS, et al. High risk of fractures within 7 years of diagnosis in Asian patients with inflammatory bowel diseases. *Clin Gastroenterol Hepatol* 2021 [Epub ahead of print] (co-corresponding author)
12. Choi SJ, Ahn SM, Oh JS, et al. Anti-tumor necrosis factor-induced lupus in patients with inflammatory bowel disease: A hospital-based cohort study from Korea. *Therap Adv Gastroenterol* 2021 Mar 3;14:1756284821997794. (co-corresponding author)
13. Nam K, Park SH, Oh JH, et al. Prevalence and risk factors of bowel symptoms in Korean patients with ulcerative colitis in endoscopic remission: a retrospective study. *BMC Gastroenterol* 2021 Jan;21:13. (corresponding author)
14. Park SH, Jeong SK, Lee JH, et al. Clinical characteristics and long-term prognosis of elderly-onset ulcerative colitis in a population-based cohort in the Songpa-Kangdong district of Seoul, Korea. *Gut Liver*. 2021 Sep 15;15(5):742-751.
15. Kim JY, Park SH, Park JC, et al. The clinical significance of anastomotic ulcers after ileocolic resection to predict postoperative recurrence of Crohn's disease. *Dig Dis Sci*. 2021 Sep;66(9):3132-3140. (corresponding author)
16. Park SH, Kim HJ, Lee CK, et al. Safety and optimal timing of BCG vaccination in infants born to mothers receiving anti-TNF therapy for inflammatory bowel disease. *J Crohns Colitis*. 2020 Dec;14(12):1780-1784.
17. Lee SH, Chang K, Seo KS, et al. Changes in prevalence and perception of complementary and alternative medicine use in Korean inflammatory bowel disease patients: results of an 8-year follow-up survey. *Intest Res*. 2020 Apr;18(2):192-199. (corresponding author)
18. Park SH, Park JC, Lukas M, et al. Biosimilars: concept, current status, and future perspectives in inflammatory bowel diseases. *Intest Res*. 2020 Jan;18(1):34-44. (co-corresponding author)
19. Cha JM, Park SH, Rhee KH, et al. Long-term prognosis of ulcerative colitis and its temporal changes between 1986 and 2015 in a population-based cohort in the Songpa-Kangdong district of Seoul, Korea. *Gut* 2020 Aug;69(8):1432-1440. (co-first author)
20. Park SH, Al-Bawardy B, Aniwani S, et al. Distinct Cutoff Values of Adalimumab Trough Levels Are Associated With Different Therapeutic Outcomes in Patients with Inflammatory Bowel Disease. *Crohns Colitis* 360. 2019 Oct;1(3):otz047 (co-corresponding author)
21. Kim JY, Yoon H, Hwang JS, et al. Comparison of Disease-related Knowledge of Patients with Inflammatory Bowel Disease between the West and the East using an Updated Questionnaire (IBD-KNOW). *J Clin Gastroenterol* 2020 Sep;54(8):720-724. (co-corresponding author)
22. Park SH, Hwang SW, Ye BD, et al. Concordance regarding disease type and phenotypic characteristics among patients with familial inflammatory bowel disease. *J Gastroenterol Hepatol*. 2020 Jun;35(6):988-993.
23. Nam K, Park SH, Lee J, et al. The Incidence and Risk Factors of *Pneumocystis jirovecii* Pneumonia in Korean Patients with Inflammatory Bowel Disease. *J Gastroenterol Hepatol*. 2020 Feb;35(2):218-224. (corresponding author)
24. Park SH, Hong M, Lee HS, et al. Association of TRAP1 with Infliximab-Induced Mucosal Healing in Crohn's disease. *J Gastroenterol Hepatol*. 2019 Dec;34(12):2118-2125.
25. Park SH, Kim YJ, Rhee KH, et al. A 30-year trend analysis in the epidemiology of inflammatory bowel disease in the Songpa-Kangdong District of Seoul, Korea in 1986–2015. *J Crohns Colitis*. 2019 Oct 28;13(11):1410-1417
26. Park SH, Aniwani S, Scott Harmsen W, et al. Update on the Natural Course of Fistulizing Perianal Crohn's Disease in a Population-Based Cohort. *Inflamm Bowel Dis*. 2019 May 4;25(6):1054-1060.
27. Choi IY, Park SH, Park SH, et al. CT Enterography for Surveillance of Anastomotic Recurrence within 12 Months of Bowel Resection in Patients with Crohn's Disease: An Observational Study Using an 8-Year Registry. *Korean J Radiol*. 2017 Nov-Dec;18(6):906-914. (co-first author)
28. Park SH, Aniwani S, Loftus EV Jr. Advances in the use of biologics and other novel drugs for managing inflammatory bowel disease. *Curr Opin Pharmacol*. 2017 Dec;37:65-71.
29. Aniwani S, Park SH, Loftus EV Jr. Epidemiology, Natural History, and Risk Stratification of Crohn's Disease. *Gastroenterol Clin North Am*. 2017 Sep;46(3):463-480. (co-first author)
30. Bae JH, Park SH, Ye BD, et al. Development and Validation of a Novel Prediction Model for Differential Diagnosis Between Crohn's Disease and Intestinal Tuberculosis. *Inflamm Bowel Dis*. 2017 Sep;23(9):1614-1623. (co-first author)
31. Seo H, Chang K, Lee SH, et al. Long-term outcomes of infliximab treatment and predictors of response in 195 patients with ulcerative colitis: a hospital-based cohort study from Korea. *Scand J Gastroenterol*. 2017 Aug;52(8):857-863. (corresponding author)
32. Oh EH, Ko DH, Seo H, et al. Clinical correlations of infliximab trough levels and antibodies to infliximab in South Korean patients with Crohn's disease. *World J Gastroenterol*. 2017 Feb 28;23(8):1489-1496. (corresponding author)

Honors & Awards

--